Quotient & KWS partner to boost antimicrobial service offering

By Nick Taylor

- Last updated on GMT

Related tags: Microbiology, Infectious disease, Infection

Quotient and KWS have partnered to support discovery and development in the fast growing antimicrobial agent sector.

Partnering combines Quotient Bioresearch’s capabilities in in-vitro ​testing, clinical services and other areas with disease model expertise at KWS BioTest. Bringing together these capabilities allows the partners to meet antimicrobial development needs from “plate to patient​”.

KWS and Quotient have referred clients to each other for a several years but the relationship has always been at “arms length​”, Ian Morrissey, director of anti-infectives at Quotient, told Outsourcing-Pharma.

Having inked the partnership Quotient and KWS will offer an integrated package and the option of a single contract for services from both companies. Openness and transparency will be needed to make the partnership work and Morrissey expects this to improve efficiency at both companies.

Services offered span support for discovery through to the clinic. Demand for these services is on the rise after resistance concerns and the emergence of alternatives to antibiotics kick-started a fairly stagnant sector, Neil Williams, director of science at KWS, told Outsourcing-Pharma.

Antimicrobial research and development spend is experiencing double-digit year-on-year growth, said Williams. This shift has seen infection, once a small part of sales at KWS, grow to account for around half of the business.

Building the relationship

In the mid-term Morrissey hopes to build on the relationship by adding anti-viral screening at Quotient. KWS has expertise in this area but little interest in adding large-scale screening services.

Quotient, in contrast, is very interested in entering the sector. As such, Morrissey hopes​KWS will support Quotient as it adds large-scale anti-viral screening services to complement its bacterial and fungi capabilities.

Both companies presented the partnership this week at the 21st European Congress of Clinical Microbiology and Infectious Diseases 2011 (ECCMID 2011) in Milan, Italy.

Quotient began working with KWS in 2008 when it bought BioDynamics Research. KWS had worked with BioDynamics Research since 2005 and quickly realised they had complementary services and business models. The strategic partnership formalises the relationship.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars